|Articles|June 5, 2013
From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer
Author(s)Debu Tripathy
Advertisement
Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Welireg Plus Keytruda Combination for Adjuvant Treatment of Renal Cell Carcinoma
2
A CAR-T Therapy Is Working Better Than Expected for Patients With Hard to Treat Leukemia
3
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
4
Your Tumor's Genetic Profile May Not Change Which Treatment Works Best for TNBC
5